Navigation Links
MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler
Date:1/6/2009

Dose indicated that "the combination of Nexus 6 Technology and MicroDose's dry powder inhaler will insure a continuous flow of 'real time' clinical information which will benefit physicians, patients and pharmaceutical companies."

David Evans, CEO of Nexus6 said "this partnership between Nexus6 and MicroDose will enable the drug delivery marketplace to access leading edge data collection and transmission capabilities, thereby increasing pharmaceutical adherence, improving patient well-being and reducing overall health care costs."

About the MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. Microdose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery and specialty pharmaceuticals company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies and products for the pharmaceutical and biotechnology industries.

MicroDose's partnered programs include; multi-product development and licensing agreements with Merck and Co. and Novartis, the development of an inhaled insulin product through MicroDose's QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its
'/>"/>

SOURCE MicroDose Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Horizon Therapeutics Announces Senior Management Appointments
2. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
3. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
4. ADVENTRX Announces Further Cost-Cutting Measures
5. Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project
6. West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator
9. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
10. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
11. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility ... was elected treasurer for the American Society for Reproductive ... knowledge and research in reproductive medicine. In his ... seat on the executive board and will have a ... Dr. Hill has actively supported ASRM since 1984 when ...
(Date:12/24/2014)... 23, 2014 PharmaBoardroom,s new ... today and available for free download , digs deep ... and growth in the sector today. One area ... has been in developing a homegrown pharmaceutical manufacturing base, even ... still remains some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... industry conference this week, FAIR LAWN, N.J., ... TKER), a distributor and marketer of proprietary,technology effective ... exhibit its poultry processing application, Tasker Blue, an,anti-microbial ... in Atlanta, Georgia January 23-25. Conference attendees from ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a global ... its,financial results for the fourth quarter and year ended December 31, ... at 11:00 AM ET (8:00 AM ... Dial information is as follows: ...
... NEEDHAM, Mass., Jan. 22 Hospitals and ... procedures that allow,construction projects to take place ... free white paper that addresses these challenges ... The white paper, titled "Infection Control ...
Cached Biology Technology:Tasker Products to Showcase Tasker Blue at International Poultry Expo 2Tasker Products to Showcase Tasker Blue at International Poultry Expo 3Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast 2White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... Scientists across the world are building an extensive repository ... understanding the function of the approximately 57,000 genes that ... Rice Functional Genomics Consortium recently announced the public availability ... mutations in about half of the known functional genes ...
... people are affected with retinitis pigmentosa (RP), a disease ... blindness. Now, a University of Missouri researcher has identified ... different forms of RP. This discovery will help scientists ... humans. "The same genetic mutations ...
... WASHINGTON, DC As researchers continue to examine ... ,important that people understand the differences among various ... Corn Refiners Association (CRA). Interchanging two distinctly different ... corn syrup, creates factually incorrect conclusions and misleads ...
Cached Biology News:200,000 rice mutants available worldwide for scientific investigation 2Cats' eye diseases genetically linked to diseases in humans 2Pure fructose frequently confused with high fructose corn syrup 2
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
Biology Products: